###### Key messages

What is already known about this subject?
=========================================

-   The phosphatidylinositol 3--kinase pathway is involved in the pathogenesis of proliferative disorders and autoimmunity.

What does this study add?
=========================

-   Our study demonstrate that this pathway is active in SS and that pharmacological targetting of this pathway drives disease amelioration in an animal model of sialoadenitis that recapitulates some feayures of SS.

How might this impact on clinical practice or future developments?
==================================================================

-   This proof of concept study support future development of therapeutics against PI3KD in SS.

Introduction {#s1}
============

The phosphatidylinositol 3-kinase delta isoform (PI3Kδ) belongs to the class 1 phosphoinositide-3-kinase family of intracellular lipid kinases that regulate metabolism, survival, proliferation, apoptosis, growth and cell migration.[@R1] Extensive data demonstrate a central role for PI3K signalling in several aspects of adaptive immune responses. Expression of the catalytic subunit of PI3Kδ is greatly enriched in lymphocytes. In B cells, PI3Kδ represents the predominant PI3K isoform to transduce signals derived from the B cell receptor and receptors binding B cell survival factors, cytokines, chemokines and costimulatory molecules.[@R2] Downstream signalling on PI3Kδ activation results in the activation of AKT and mTOR; the latter exists in two major protein complexes, the rapamycin-sensitive mTORC1 (in complex with raptor) and the rapamycin-insensitive mTORC2 (in complex with rictor). A key substrate of mTORC1, ribosomal protein S6 kinase (S6K), phosphorylates ribosomal protein S6 (pS6), which can thereby act as a marker of active PI3K-mTOR signalling. The sensitivity of pS6 expression to PI3Kδ signalling has been demonstrated in both T and B cells.[@R5]

The significant role of PI3Kδ in regulating B cell biology has led to the development of PI3Kδ inhibitors as therapeutics for B cell malignancies.[@R7] Idelalisib, a PI3Kδ selective inhibitor, has recently received Food and Drug Administration approval for the treatment of chronic lymphocytic leukaemia and non-Hodgkin's lymphoma (NHL). Clinical trials have demonstrated the ability of idelalisib to inhibit B cell survival and interfere with microenvironment-derived signals responsible for maintenance of malignant cells within the lymph node.[@R7] The established role of PI3Kδ in B cell hyperactivity suggest that this pathway is an attractive target for autoimmune conditions characterised by B cell hyperactivation, such as primary Sjögren's syndrome (pSS).

pSS is characterised by systemic autoantibody production and local, predominantly B cell infiltration of the exocrine glands that often results in functional loss. Cellular infiltrates are characterised by ectopic production of lymphoid chemokines, T/B cell segregation and formation of follicular dendritic cell networks within ectopic germinal centres (GC).[@R10] Moreover, local expression of *AICDA*, the gene encoding for the activation-induced cytidine deaminase (AID), the enzyme instrumental for B cell affinity maturation, is expressed in pSS GC where it is believed to support local autoantibody production.[@R12] Progressive enlargement of pSS inflammatory foci is characterised by increased accumulation of activated B cells, and in some cases, local emergence of post-GC malignant clones responsible for the development of NHL.[@R13] Dysregulated B cell activation, locally manifested by salivary gland swelling and production of anti-SSA and anti-SSB autoantibodies, is also accompanied by systemic increases in immunoglobulins and autoantibodies, including rheumatoid factor and cryoglobulins.[@R19] Additional systemic features associated with B cell hyperactivity, such as lymphadenopathy, night sweats and loss of weight are often observed during lymphoma development.[@R21] The dysfunctional humoral response present in these patients supports the investigation of PI3Kδ in pSS pathogenesis and its blockade as a therapeutic option for this condition.

Materials and methods {#s2}
=====================

Mice and salivary gland cannulation {#s2-1}
-----------------------------------

C57BL/6 mice were purchased from Charles River and were maintained under specific pathogen-free conditions in the Biomedical Service Unit at the University of Birmingham according to Home Office and local ethics committee regulations. Under ketamine/domitor anaesthesia, the submandibular glands of female C57BL/6 (8--12 weeks) were intraductally cannulated with 10^8^--10^9^ plaque-forming unit (pfu) of luciferase-encoding replication-defective adenovirus (AdV5), as previously described.[@R26] Mice were sacrificed at day 15 postcannulation (pc) (peak of organisation of the lymphoid aggregates). To collect samples, mice were given general anaesthesia as mentioned above and were then secured in the supine position. Salivation was induced by subcutaneous administration of 10 mg/kg pilocarpine (Sigma-Aldrich) in phosphate buffered saline (PBS). Saliva was collected with a pipet over a 10 min period and transferred into weighed eppendorf tubes, the tubes were then reweighed and the volume of saliva calculated (1 mg=1 µL saliva). Results were expressed as mg saliva/10 min/g body weight.

Seletalisib inhibitor {#s2-2}
---------------------

The in vitro and in vivo properties of seletalisib have been described previously.[@R27] Mice were gavaged at a dose of 10 mg/kg with seletalisib every day starting from day 0, day 3, day 5 and day 8 pc.

Human salivary gland biopsies from patients with pSS {#s2-3}
----------------------------------------------------

Minor salivary gland (mSGs) samples were obtained from the Human Biomaterials Resource Centre at the University of Birmingham under ethics number 10-018 and from the Sjögren's cohort at the University of Rome, Sapienza under ethics Harmonics H2020. Specimens were identified among samples obtained by patients diagnosed with pSS according to the 2002 American European Consensus Group Criteria criteria[@R28] and fulfilling the histological criteria for the diagnosis of pSS (presence of aggregates\>1 focus score). All patients included were untreated with immunosuppressive drugs including steroids.

Non-specific sialoadenitis samples were selected among patients undergone investigation for pSS, because of clinical symptoms of dryness (eyes and/or mouth) but either did not fulfil the classification criteria for pSS and/or were not clinically diagnosed as primary or secondary SS by the leading physician [table 1](#T1){ref-type="table"}.

###### 

Baseline characteristics of subjects included in the study

  Cohorts 1 and 2 Birmingham                       
  ---------------------------- ------------------- -------------
  Age (years)\*                63.0 (55, 67)       47 (46, 52)
  Female†                      9/9 (100)           3/3 (100)
  Anti-Ro antibody positive†   7/9 (78)            0/0 (0)
  Anti-La antibody positive†   6/9 (67)            0/0 (0)
  IgG (g/L)\*                  17.6 (12.9, 42.5)   --
  Focus score                  \>1                 N/A
  Germinal centre†             --                  N/A
  ESSDAI                       --                  --

N/A, non applicable.

  Baseline characteristic      pSS (cohort 2)        Sicca (cohort 2)
  ---------------------------- --------------------- --------------------
  Age (years)\*                56.0 (24, 57)         41 (32, 76)
  Female†                      4/5 (80)              3/5 (60)
  Anti-Ro antibody positive†   4/5 (80)              0/0 (0)
  Anti-La antibody positive†   2/5 (40)              0/0 (0)
  IgG (g/L)\*                  13.05 (9.95, 19.94)   9.26 (7.51, 13.98)
  Focus score\*                1.29 (0.8, 2.14)      N/A
  Germinal centre†             2/4 (50)              N/A
  ESSDAI                       9 (8, 17)             N/A

  Cohort 3. Rome                                   
  --------------------------------- -------------- -------------
  Age (years)\*                     48 (26,72)     55 (37,70)
  Female†                           15/17 (88.2)   15/15 (100)
  Anti-Ro antibody positive†        11/17 (64.7)   0/0 (100)
  Anti-La antibody positive†        8/17 (47.1)    0/0 (100)
  Anti-nuclear antibody positive†   12/17 (70.6)   0/0 (100)
  Hyperglobulinemia†                7/17 (41.2)    0/0 (100)
  Focus score\*                     2.8 (1,10)     N/A
  Germinal centre†                  11/17 (64.7)   N/A
  ESSDAI\*                          1 (0, 7)       0 (0, 2)

\*Median (range).

†Number positive (%).

BAFF, B cell activating factor; ESSDAI, EULAR Sjögren's Syndrome Disease Activity Index; Ig, immunoglobulin; pSS, primary Sjögren's syndrome.

On patients collected between 2012 and 2018, EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) data were available and reported in [table 1](#T1){ref-type="table"}.

Histology and immunofluorescence {#s2-4}
--------------------------------

Immunofluorescence (IF) staining was performed as previously described on formalin-fixed, paraffin-embedded (FFPE) labial salivary gland biopsies from patients with SS[@R10] and on murine SGs obtained from virus cannulated and control mice.[@R30]

The following antibodies were used: for mouse CD45 clone 30-F11, CD19 clone eBio1D3 and CD3e clone ebio500A2 (from eBiosciences) and for humans CD3 polyclonal rabbit or monoclonal mouse (Dako), CD20 clone L26 (Dako), CD138 and CD68 (Abd Serotech) and pS6 polyclonal rabbit (Cell signalling).

RNAScope {#s2-5}
--------

IF staining was performed as previously described on FFPE labial salivary gland biopsies from patients with SS.[@R10] Samples were probed for PI3KCD ref.520988 (ACDBio) following manufacturer's instructions (ACDBio). Samples were double stained with antihuman CD45 NCL-L-LCA (Leica).

Enzymatic digestion and isolation of cells {#s2-6}
------------------------------------------

ADV5 infected SGs from seletalisib-treated and vehicle-treated mice were isolated from culled animals at different time points. Glands were dissected and placed in 1 mL of RPMI-1640 (with 2% fetal calf serum (FCS)) on ice. Once all SGs were collected, RPMI-1640 was removed, replaced with 2 mL enzyme mix (RPMI with 2% FCS, 0.8 mg/mL dispase, 0.2 mg/mL collagenase P and 0.1 mg/mL DNase I) and digested as previously described.[@R31]

Flow cytometry analysis and sorting {#s2-7}
-----------------------------------

Single cell suspensions were incubated with 100 µL diluted antibodies for 30 min at 4°C in ice-cold fluorescence-activated cell sorting (FACS) buffer (0.5% bovine serum albumin, 2 mM EDTA in PBS) with 'cocktails' of the following antibodies: CD45 clone 30-F11, CD3e clone 145--2 C11, CD4 clone RM4-5, CD62L clone MEL-14, CD44 clone IM7, CD8a clone 53--6.7, B220 clone RA3-6B2, CD23 clone B3B4, CD19 clone 1D3 and CD5 clone 53--7.3 (all from eBiosciences), CD21 clone 7G6 (BD biosciences) and CD11c clone N418, F4/80 clone BM8, CD64 clone X54-5/7.1 and NK1.1 clone PK136. Intracellular staining for Ki67 clone B56 (BD Biosciences) and pS6 PE and pAKT Alexa Fluor 488 (Cell signalling) was performed by using the Cytofix/Perm kit (BD biosciences) and Fixation/Permeabilization Buffer set (ebiosciences) according to the manufacturer's protocol. Cells were resuspended in FACS buffer and then analysed using a Cyan-ADP (Dako) or Fortessa (BD) with forward/side scatter gates set to exclude non-viable cells. Cells of interest were sorted by using BD FACSAria. Data were analysed with FlowJo software (Tree Star).

Microdissection, mRNA isolation, qRT-PCR {#s2-8}
----------------------------------------

Microdissection and laser catapulting were performed on Cresyl-violet (0.1% in ethanol)-stained frozen tissue sections from salivary gland samples and tonsil GCs as previously described.[@R32]

Total RNA was isolated either from murine and human SGs with an RNeasy mini kit (Qiagen), from microdissected tissue or from sorted cells. RNA was then reverse transcribed using the high capacity reverse transcription cDNA synthesis kit (Applied Biosystems) according to the manufacturer's specifications. Reverse transcription was carried out on a Techne 312 Thermal Cycler PCR machine. Quantitative real-time (qRT)-PCR (Applied Biosystems) was performed on cDNA samples for *ccl19*, *cxcl13*, *lta*, *ltb* and *baff* mRNA expression. β-actin and pdgfrβ were used as an endogenous control. The primers and probes used were from Applied Biosystems ([table 2](#T2){ref-type="table"}). qRT-PCR was run in duplicates on a 384-well PCR plate (Applied Biosystems) and detected using an ABI PRISM 7900HT instrument. Results were analysed with the Applied Biosystems SDS software (SDS V.2.3) as previously described.[@R30]

###### 

Primers and probes used for quantitative PCR

  Gene            Assay ID
  --------------- ---------------
  Mouse β-actin   Mm01205647_g1
  Mouse Pdgfrβ    Mm00435546_m1
  Mouse AICDA     Mm00507774_m1
  Mouse BAFF      Mm00840578_g1
  Mouse CXCL13    Mm00444533_m1
  Mouse CXCR5     Mm00432086_m1
  Mouse CCL19     Mm00839967_g1
  Mouse CCR7      Mm01301785_m1
  Mouse CXCL12    Mm00445553_m1
  Mouse CXCR4     Mm01292123_m1
  Mouse LTβ       Mm00484254_m1
  Mouse LTα       Mm00484254_m1
  Mouse IL-23     Mm00484254_m1
  Mouse IL-6      Mm00434256_m1
  Mouse IFNγ      Mm00434774_g1
  Mouse TNFα      Mm00443258_m1
  Mouse IL-1β     Mm00434228_m1

Lipid analysis {#s2-9}
--------------

Salivary gland tissue was pulverised in liquid nitrogen using a mortar and pestle and determination of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) levels, including lipid extraction, derivatisation and mass spectrometric analysis, was carried out as described previously.[@R33]

Results {#s3}
=======

Target validation of PI3Kδ pathway engagement in SGs of patient with pSS {#s3-1}
------------------------------------------------------------------------

We confirmed the expression of PI3KCD transcript mRNA name for PI3Kδ in sorted peripheral blood mononuclear cell from patients with pSS ([figure 1A](#F1){ref-type="fig"}) and in total mRNA isolated from minor SGs from pSS and sicca controls ([figure 1B](#F1){ref-type="fig"}). Transcript levels of PI3KCD significantly correlated with the focus score (FSC) calculated in the same SGs ([figure 1C](#F1){ref-type="fig"}) and associate with immune activation markers such as the presence of autoantibodies, hyperglobulinaemia and the presence of GCs ([online supplementary figure 1](#SP1){ref-type="supplementary-material"}). qRT-PCR on microdissected tissue and RNAScope confirmed localisation of the transcript for PI3Kδ within the foci and in particular within GC+foci ([figure 1D,E](#F1){ref-type="fig"} and control tonsil in the [online supplementary figure 1](#SP1){ref-type="supplementary-material"}).
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![(A) Quantitative real-time (qRT)-PCR analysis of PI3KCD transcripts in peripheral blood mononuclear cell (PBMC) isolated from patients with primary Sjögren's syndrome (pSS). CD3+ cells (dark grey bar), CD19+ cells (black bar), CD138+ cells (red bar), CD11c+CD11b+ cells (light grey bar). Results represented as mean±SD of five patients; \*\*p\<0.01, one-way analysis of variance (ANOVA). (B) qRT-PCR analysis of PI3KCD transcripts in total mRNA isolated from salivary glands of patients with pSS (black circles) and sicca controls (open circles). Results represented as mean±SD of 15--17 patients in each group; \*p\<0.05, unpaired t-test. (C) Correlation between focus scores (FSC) and levels of PI3KDC expressed as 2\^-DCT detected in frozen salivary galnds from patients with pSS. R^2^ 0.3941, p=0.0092. (D) qRT-PCR analysis of PI3KCD transcripts in microdissected epithelium, foci, germinal centre positive (GC+) foci from salivary glands of patients with pSS and GCs isolated from tonsils. Results represented as mean±SD of 5--10 biological replicates in each category; \*\*p\<0.01, \*\*\*\*p\<0.0001, one-way ANOVA. (E) Microphotograph of minor salivary glands from patients with pSS, showing in red CD45 staining and in green PI3KCD RNA (visualised with RNAScope). (F) Representative microphotograph of salivary glands from non-specific sialoadenitis control (NSCS) patients stained for the PI3Kδ pathway activation marker phosphorylated ribosomal protein S6 (pS6; green) and 4′,6-diamidino-2-phenylindole (DAPI; grey); scale bars=100 µm. (G) Representative microphotograph of salivary glands from patients with pSS with pS6 (green) and DAPI (grey). (H) Representative microphotographs showing pS6 (green) expression within CD20 (blue) and CD3 or CD138 (red) cells in salivary glands from patients with pSS; scale bars=100 µm. (I) Representative histogram showing flow cytometry staining for pS6 (green) and isotype control (grey) in CD45+ cells present in salivary glands of patients with pSS. viSNE plots of flow cytometry of pSS salivary gland CD45+pS6+ cells. Colours indicate cell expression level of labelled marker. Histogram showing pAkt expression in CD45+pS6+ cells.](annrheumdis-2017-212619f01){#F1}

In order to assess activation of the PI3Kδ pathway in minor SG biopsies and confirm its local engagement, we used IF to detect the presence of the phosphorylated ribosomal protein S6 (pS6),[@R27] in pSS and non-specific sialoadenitis control (NSCS) tissue. Significant expression of pS6 was observed in salivary gland biopsies of patients with pSS as compared with non-specific sialoadenitis. In NSCS, pS6 staining was only detected within the epithelium and not present in all samples analysed ([figure 1F](#F1){ref-type="fig"}). On the contrary, in pSS, intense pS6 staining was detected within the lymphoid aggregates and on the periphery of the foci, in co-localisation with T (CD3+) and B (CD20+) cells and myeloid cells ([figure 1G,H](#F1){ref-type="fig"} and [online supplementary figure 1](#SP1){ref-type="supplementary-material"} for pSS and tonsil GC, used as control). This correlated with the extent of infiltration of the glands ([online supplementary figure 1](#SP1){ref-type="supplementary-material"}).

Interestingly, intense pS6 staining was detected in co-localization with CD138+ plasma cells in pSS SGs as demonstrated by IF and flow cytometry ([figure 1H,I](#F1){ref-type="fig"}). pS6 positive cells encompassed also T, B and dendritic cells (DCs) and AKT activation ([figure 1I](#F1){ref-type="fig"}).

These data suggest that PI3Kδ is engaged in several cell types within pSS inflammatory infiltrates and might be involved in the perpetuation of the local autoimmune response.

Blockade of PI3Kδ pathway reverses lymphocytic infiltration in a mouse model of focal sialoadenitis {#s3-2}
---------------------------------------------------------------------------------------------------

The in vivo functional role and downstream effect of PI3Kδ inhibition in pSS was tested taking advantage of a mouse model of focal sialoadenitis induced by direct delivery of a replication-deficient ADV5 within murine wild-type SGs.[@R26] Localised viral infection in this model mimics features of pSS, including the formation of focal lymphocytic aggregates, expression of lymphoid chemokines and cytokines as well as antinuclear antibodies.[@R26] First, expression of PI3KCD was confirmed in the CD45+ compartment of cannulated SGs from mice sacrificed at day 15 pc ([figure 2A](#F2){ref-type="fig"}). Engagement of the pathway was confirmed by upregulation of pS6 and pAKT on isolated CD45+ cells, with a predominant expression in DCs, T cells, B cells and plasma cells ([figure 2B--D](#F2){ref-type="fig"}). The large predominance of pS6+ DC in our model is probably related to the viral nature of the stimulus and is not reflecting entirely human pSS where the percentage of pS6+ cells only accounted for a minority of the CD11c+ and CD11b+ cells. Treatment of mice with seletalisib resulted in a significant decrease in the ratio between PIP3 and phosphatidylinositol (4,5)-biphosphate (PIP2), which demonstrated blockade of the PI3Kδ pathway ([figure 2E](#F2){ref-type="fig"}). Moreover, seletalisib treatment induced downregulation of S6 phosphorylation in CD45+ cells isolated from infected SGs in treated mice but not in vehicle controls ([figure 2F](#F2){ref-type="fig"}). Together, these data confirmed the activation of the PI3Kδ pathway in our model and the ability to modulate it by using seletalisib. ADV5 infected mice treated with seletalisib, either prophylactically (day 0 pc) or therapeutically (at day 3, 5 or 8 pc) showed a reduction in the absolute number of CD45+ cells in active treatment groups as compared with the vehicle-treated mice. This significant decrease was maintained in a full therapeutic regime when mice were treated from either day 3 or 5 pc ([figure 3A](#F3){ref-type="fig"}). Although this significant reduction in CD45+ cell counts was not maintained when treated day 8 pc, a significant reduction was observed in specific immune cell populations, notably T and B cells ([online supplementary figure 2](#SP2){ref-type="supplementary-material"}). Together, these data confirm the therapeutic potential of this drug in established disease. Flow cytometry analysis revealed a marked reduction in absolute numbers of CD3+ T cells (both CD4 and CD8 cells) ([figure 3B--D](#F3){ref-type="fig"}) as well as CD19+ B cells in all active treatment groups relative to controls ([figure 3E](#F3){ref-type="fig"}). Within the overall T cell population, memory and effector CD4 and CD8+ cells were both affected ([online supplementary figure 3](#SP3){ref-type="supplementary-material"}). Moreover, all subsets of B cells (B1A, B1b, B1c, B2, marginal zone and follicular B cells) displayed marked decreases in absolute cell numbers ([figure 3F--G](#F3){ref-type="fig"} and [online supplementary figure 4](#SP4){ref-type="supplementary-material"}). In addition, the proliferative ability of both T and B lymphocytes was impaired as demonstrated by a significant decrease in Ki67 staining in both the T and B compartment ([figure 3H--I](#F3){ref-type="fig"}).
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![(A) Quantitative real-time PCR analysis of PI3KCD transcripts isolated cells from salivary glands of cannulated mice at day 15 postcannulation (pc). B cells (black bar), T cells (dark grey bar), plasma cells (red bar), macrophages (blue) and dendritic cells (light grey bar), CD45− cells (light yellow bars). Results represented as mean±SD from five mice; \*p\<0.5, \*\*\*p\<0.001, one-way analysis of variance. (B) Pie chart showing distribution of different leucocyte populations within CD45+ phosphorylated ribosomal protein S6 (pS6+) cells present in salivary glands of wild-type (WT) mice at day 15 pc (C) viSNE plots of flow cytometry of day 15 pc salivary gland CD45+pS6+ cells. Colour indicates cell expression level of labelled marker. Data is representative of two independent experiments with five mice. (D) Histogram showing phosphorylation of Akt in CD45+pS6+ cells in salivary glands of WT mice at day 15 pc. (E) Graphs showing phosphatidylinositol (3,4,5)-trisphosphate (PIP3)/phosphatidylinositol (4,5)-biphosphate (PIP2) ratio in salivary glands of mice treated with seletalisib versus vehicle control to demonstrate effect of the compound directly in the salivary glands. Results represented as mean±SD of three independent experiments with five mice per group; \*\*p\<0.01, unpaired t-test. (F) Histogram showing pS6 expression levels within the CD45+ cells in day 15 pc salivary glands of mice treated with seletalisib as compared with the vehicle-treated mice. Isotype control also shown. The mice were treated with seletalisib or vehicle from day 12 pc onwards. Data is representative of experiments with three mice in each group.](annrheumdis-2017-212619f02){#F2}

![(A) Graphs summarising flow cytometry data for absolute numbers of CD45 cells in salivary glands of wild-type (WT) mice at day 15 postcannulation (pc) treated with seletalisib at day 0 (white bars), day 3 (light grey) and day 5 (dark grey) pc as compared with vehicle controls (black bars). Results represented as mean±SD of two independent experiments with five mice per group; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, one-way analysis of variance (ANOVA). (B) Graphs summarising flow cytometry data for absolute numbers of CD3+ T cells in salivary glands of WT mice at day 15 pc treated with seletalisib at day 0 (white bars), day 3 (light grey) and day 5 (dark grey) pc as compared with vehicle controls (black bars). Results represented as mean±SD of two independent experiments with five mice; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, one-way ANOVA. (C and D) Graphs summarising flow cytometry data for absolute numbers of CD4+ T cells, CD8+ T cells in salivary glands of WT mice at day 15 pc treated with seletalisib at day 0 (white bars), day 3 (light grey) and day 5 (dark grey) pc as compared with vehicle controls (black bars). Results represented as mean±SD of two independent experiments with three mice per group; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, one-way ANOVA. (E) Graphs summarising flow cytometry data for absolute numbers of CD19+ B cells in salivary glands of WT mice at day 15 pc treated with seletalisib at day 0 (white bars), day 3 (light grey) and day 5 (dark grey) pc as compared with vehicle controls (black bars). Results represented as mean±SD of two independent experiments with five mice glands per group; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, one-way ANOVA. (F--I) Graphs summarising flow cytometry data for absolute numbers of CD19+CD11b−CD5−B2 B cells, follicular (CD23+) B cells and Ki67+ (proliferating) T and B cells in salivary glands of WT mice at day 15 pc treated with seletalisib at day 0 (white bars), day 3 (light grey) and day 5 (dark grey) pc as compared with vehicle controls (black bars). Results represented as mean±SD of two independent experiments with three mice per group; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, one-way ANOVA. (J) Graphs summarising flow cytometry data for absolute numbers of B220+ CD138+ plasma cells in salivary glands of WT mice at day 15 pc treated with seletalisib at day 0 (white bars), day 3 (light grey) and day 5 (dark grey) pc as compared with vehicle controls (black bars). Results represented as mean±SD of two independent experiments with five mice per group; \*\*p\<0.01, \*\*\*p\<0.001, one-way ANOVA.](annrheumdis-2017-212619f03){#F3}

Following our observation of PI3Kδ activation in CD138+ plasma cells, we also explored the effect of seletalisib on this cell type in cannulated mice treated either with the compound or its vehicle. Inhibition of PI3Kδ resulted in a significant decline in the number of CD138+ plasma cells in all treatment groups, suggesting that the PI3Kδ pathway also regulates plasma cell homeostasis ([figure 3J](#F3){ref-type="fig"}).

Interestingly, the effects observed on specific subpopulations can be different depending on the treatment regime used. While we did not observe a selective effect in samples treated prophylactically or from day 3 pc, we have observed a significant effect on all B cells as percentages (as well as absolute numbers) and in particular on B1a and MZ B cells in animals treated from day 5 pc ([online supplementary figures 4 and 5](#SP4 SP5){ref-type="supplementary-material"}).

Aggregate formation during salivary gland inflammation is abrogated in mice treated with seletalisib {#s3-3}
----------------------------------------------------------------------------------------------------

Having observed a reduction in lymphocyte accumulation within SGs following seletalisib by flow cytometry, we wanted to confirm these observations by IF staining for CD3+ and CD19+ cells as well as to visualise any impact on the organisation of infiltrating lymphocytes. These data revealed impaired lymphoid aggregate formation in seletalisib-treated mice compared with those treated with vehicle. It was particularly marked in mice treated prophylactically with seletalisib, in which no visible lymphoid aggregate formation was evident. This was confirmed by quantification of the FSC, foci size and aggregate organisation, with all parameters demonstrating a significant reduction in the treated animals at day 15 pc as compared with the controls ([figure 4A--C](#F4){ref-type="fig"}). Importantly, the abrogation of lymphocytic foci formation and organisation coincided with a decrease in antinuclear autoantibody production in mice treated with the PI3kδ inhibitor compound as compared with vehicle controls ([figure 4](#F4){ref-type="fig"} and [online supplementary figure 4](#SP4){ref-type="supplementary-material"}). Analysis of stimulated salivary flow also showed a significant improvement in saliva production in seletalisib-treated mice ([figure 4E](#F4){ref-type="fig"}).

![(A and B) Microphotograph of lymphoid aggregates in salivary glands of wild-type (WT) mice at day 15 postcannulation (pc) treated with seletalisib prophylactically or therapeutically as compared with vehicle controls (black bars) stained for CD3 (red) and CD19 (green). Scale bars=500 µm (tile scans) and 100 µm (foci snapshots). (C) Graphs represent the focus score (number of lymphocytic foci (\>50 lymphocytes) per 4 mm^2^), average size of foci and percentage of segregated aggregates in cannulated salivary glands from therapeutically treated mice as compared with controls. Results represented as mean±SE of two independent experiments with five mice per group; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, unpaired t-test. (D) Graphs represent percentage of antinuclear antibodies (ANA) positive mice from seletalisib-treated mice as compared with controls. Results represented as mean±SD of two independent experiments with 10 mice per group, unpaired t-test. (E) Graph comparing salivary flow in seletalisib-treated mice and vehicle controls measured at day 15 pc. Salivary flow is measured as milligrams of saliva produced in 10 min/body weight following pilocarpine stimulation (see the Methods section). Results represented as mean±SD of three independent experiments with 10 mice per group, unpaired t-test.](annrheumdis-2017-212619f04){#F4}

Inhibition of PI3Kδ pathway impairs the expression of ectopic lymphoneogenesis associated cytokines and chemokines {#s3-4}
------------------------------------------------------------------------------------------------------------------

The reduced lymphocyte aggregation following seletalisib treatment led us to investigate its impact on the expression of factors that drive ectopic lymphoneogenesis. In accordance with the histological findings, qRT-PCR performed on whole SG tissue demonstrated significantly reduced transcript levels for the lymphoid cytokines (LTβ and LTα) in mice treated with seletalisib as compared with controls. Moreover, a significant reduction in CXCL13 and CXCL12 transcript levels was observed in seletalisib-treated mice, while a modest effect was observed for CCL19, one of the chemokines responsible for T cell migration within the affected glands. To further support the lymphoid chemokine expression and aggregate histological data, qRT-PCR analysis for CXCR5, CCR7 and CXCR4 mRNA also showed significantly lower transcript levels in seletalisib-treated mice when compared with vehicle controls. A significant reduction in B cell activating factor (BAFF) expression across all treatment groups tested as compared with vehicle-treated mice was also detected. Furthermore, marked suppression in AICDA mRNA transcripts (the gene encoding for AID) was observed in mice treated with PI3Kδ inhibitor ([figure 5A](#F5){ref-type="fig"}).

![(A) Quantitative real-time-PCR analysis of ltα, ltβ, cxcl13, ccl19, cxcl12, cxcr5, ccr7, cxcr4, baff and aicda mRNA transcripts in salivary glands of wild-type mice at day 15 postcannulation (pc) treated with seletalisib at day 0 (white bars), day 3 (light grey) and day 5 (dark grey) pc as compared with vehicle controls (black bars). Results represented as mean±SD of two independent experiments with five mice per group; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, one-way analysis of variance (ANOVA). (B) Microphotograph showing CXCL13 and CCL21 protein expression (green) in day 15 ADV5-infected salivary glands from seletalisib-treated mice as compared with vehicle. T cells (CD3 red) and B cells (CD19 green) are also shown. Scale bars=20 µm.](annrheumdis-2017-212619f05){#F5}

IF analysis demonstrated decreased protein expression for CXCL13 and CCL21 in the mice analysed ([figure 5B](#F5){ref-type="fig"}).

Overall, these results suggest that inhibition of the PI3Kδ pathway disrupts the positive feedback loop of lymphocytic infiltration and lymphoid chemokine production which is required for the establishment of ectopic GC and plasma cell survival niches in the affected SGs.

Interestingly, control lymphoid tissue obtained from mice treated with seletalisib (lymph node and blood) showed minimal impact of the drug on circulating B cells and in the lymph node on the CD4/CD8 ratio ([online supplementary figure 6](#SP6){ref-type="supplementary-material"}). The anatomical structure of the secondary lymphoid organs was fully conserved in these animals (data not shown).
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Discussion {#s4}
==========

Here, we provide evidence that the PI3Kδ pathway is active and functional in pSS and its blockade in vivo interferes with local and systemic disease progression in an animal model of focal sialoadenitis.

Aberrant B cell activation is the hallmark of pSS. B cell number rises in the SGs during disease progression, correlating with a higher FSC, higher autoantibody titres and the presence of systemic manifestations.[@R10] The increased risk of lymphoma development also correlates with the progressive aggregation of B cells within the SGs and, while a positive association between lymphoma development and GC formation has not been established, the negative predictive value of the absence of GC in lymphomagenesis seems clear.[@R13] More recently, an increased frequency of transitional B cells and mature naive B cells expressing polyreactive antibodies has been demonstrated in the peripheral blood of patients with pSS, confirming that impaired peripheral B cell tolerance plays a critical role in pSS pathogenesis.[@R38] Accordingly, we previously demonstrated that altering B cell recruitment by blocking the interleukin (IL)-22 mediated production of CXCL13 reduces the formation of SG aggregates and abrogates production of autoantibodies in a mouse model of pSS.[@R30]

PI3Kδ regulates key aspects of B cell homeostasis. B cells derived from mice deficient in PI3Kδ activity or wild type B cells treated with the PI3Kδ inhibitor all display reduced proliferative ability and increased susceptibility to apoptosis in response to anti-CD40, IL-4 or anti-IgM stimulation.[@R39] Moreover, both B cell response to the BAFF[@R41] and to the chemoattractant CXCL13 and shingosine-1-phosphate (S1P) largely relies on PI3Kδ via activation of Rap1, a key GTPase in B lymphocyte migration.[@R42] Memory T cell generation and function is also impaired in the absence of PI3Kδ[@R6]; thus, unsurprisingly, T cell-dependent antibody responses are also affected in the absence of PI3Kδ isoform.[@R44] Finally, PI3Kδ-deficient lymphocytes are unable to form polarised synapses efficiently.[@R44]

While the rationale for PI3Kδ targeting in B cell driven autoimmune condition is clear, target validation has not been reported for pSS. Here we demonstrate that the PI3Kδ pathway is activated in pSS and clearly differentiates pSS samples from control sialoadenitis. Expression of the PI3Kδ transcript correlates with manifestations of B cell hyperactivity, including autoantibody production, formation of GCs and hyperglobulinaemia. The expression of pS6, a downstream adaptor of the PI3Kδ pathway, was anticipated in T and B lymphocytes but this marker was also detected in myeloid cells and plasma cells. This finding suggests that patients with pSS and in particular those manifesting B cell symptoms and those characterised by a 'plasma cell signature'[@R46] have an increased engagement of the PI3Kδ pathway and would benefit from a treatment targeting its activation.

We used a small molecule seletalisib (UCB Celltech), previously demonstrated to be safe and efficacious in patients with psoriasis,[@R27] to target this pathway in vivo, in a model of inducible sialoadenitis.[@R26] Treatment of cannulated mice with seletalisib resulted in downregulation of S6 phosphorylation and decreased conversion of PIP2 in PIP3, demonstrating the ability of seletalisib to inhibit PI3Kδ activation in treated samples. PI3Kδ blockade in the SGs of our murine model resulted in significantly decreased lymphocyte infiltration, both in terms of T and B cells, disrupted lymphocyte organisation, reduction in autoantibody production, abrogated transcription of lymphoid chemokines and cytokines and improvement in saliva production. In peripheral organs, we observed a non-significant decreased on total cellularity and some changes in the T/B cell ratio and CD4/CD8 ratio. In the blood, we observed a more profound effect on cellularity, probably due to bioavailability and a decrease in total B cell number. Importantly and in agreement with previous publications in human,[@R27] including a recent study in pSS,[@R48] the mice did not show any sign of infection or unexplained weight loss.

It has been previously demonstrated by us and others that lymphocytes, and in particular T cells, imprint the local microenvironment by releasing LTα, β and proinflammatory cytokines, such as IL-22 or IL-17 that, in turn, regulate the expression of lymphoid chemokines and survival factors necessary for ectopic lymphocyte homing and maintenance in the tissue.[@R30] Here we establish that inhibition of PI3Kδ, in seletalisib-treated mice, affects both T and B cells, directly interfering with the establishment of the pathogenic SG microenvironment, preventing the formation of the GC and the perpetuation of local disease.[@R10] These data are in line with previous reports highlighting the role of PI3Kδ in the differentiation of T cells into T helper cells, required for effective GC responses and antibody production.[@R45] Accordingly, in our model, abrogation of tissue pathology was accompanied by decreased autoantibody production.

While the effect on antigen presentation and B cell function have been largely described[@R4] and hereby confirmed by the decrease in IL-23 and DC number in the SGs, blood and lymph node, our data highlight a clear requirement for this pathway on plasma cells in our model. In patients with pSS, the aberrant levels of autoantibodies and immunoglobulin are used as biomarkers for disease activity and prognosis.[@R20] GC in the SGs are able to support B cell affinity maturation; moreover, Ro+ and La+ plasma cells have been demonstrated at the periphery of large intraglandular foci. The detection of long-lived CD138+ Bcl-2+ plasma cells in pSS SG has also been associated with higher FSCs,[@R60] more severe systemic manifestation and increased lymphoma risk,[@R23] thus establishing that in pSS, local and systemic activation of the plasma cell compartment is involved in disease progression. Here, we demonstrate intense pS6 staining within SG infiltrating plasma cells, suggesting that even on activation, plasma cells are reliant on the PI3Kδ pathway for homeostatic maintenance. Accordingly, in vivo treatment with seletalisib significantly affects plasma cell numbers and abrogates autoantibody production in murine sialoadenitis. Similar data on the efficacy of a PI3Kδ blocking agent have been reported in a phase 2 study, showing a decrease in immunoglobulins in pSS-treated patients as compared with placebo. While primary endpoints were not met in this first study, effects on plasma cells and safety profile from this study support the continued investigation of PI3Kδ inhibitors such as seletalisib in pSS.[@R48]

All together, these data and the significant correlation between PI3Kδ expression in the glands and clinical manifestations associated with B cell hyperactivation strongly support the evaluation of seletalisib in patients characterised by systemic manifestations, including high levels of immunoglobulins, presence of GCs and high FSC in the biopsies, often identifiable with high levels of ESSDAI.[@R70]

In pSS, B cell-depleting agents, such as rituximab, failed to demonstrate significant clinical success in phase 3 randomised clinical trials, and disease relapse has been observed in patients with pSS (and lymphoma) treated with rituximab.[@R76] While these disappointing findings with rituxumab might in part be due to trial design and choice of outcome measure, biologically, there is evidence of expansion of pathogenic B cell clones following depletion, allegedly supported by the persistent production of survival and chemotactic factors in the SG microenvironment.[@R77] Of note, rituximab is unable to target long-lived plasma cells (CD20 negative) directly, thus leaving the autoantibody producing reservoir intact.[@R85] Consequently, a strategy that aims to target plasma cells directly, alongside T and B lymphocytes, using an agent such as seletalisib, would be desirable in patients with pSS presenting a clear plasma cell signature.[@R46] Our findings, confirm that in pSS, PI3Kδ has a pleotropic effect on the homeostasis of T, B lymphocytes (including GC B cells) and plasma cells. Selective targeting of PI3Kδ using seletalisib significantly impacts pathogenic microenvironment in the inflamed murine glands, while affecting, systemically, the production of autoantibodies. Overall, these results appear to confirm a mechanistic role for PI3Kδ activity in the immunopathogenesis of pSS supporting the presence and engagement of this pathway in patients characterised by local and systemic B cell hyperactivity. Overall, these results appear to confirm a mechanistic role for PI3Kδ activity in the immunopathogenesis of pSS supporting the presence and engagement of this pathway in human pSS salivary gland and warranting the further evaluation of seletalisib in clinical trials in patients with pSS.
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